-- Funds to Support Advancement of Pipeline and Discovery Programs, Including Recently Initiated Phase 1 Trial of Lead Candidate CT-0508 -- PHILADELPHIA, March 1, 2021-- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA's total capital raised to date to nearly $121 million. The second closing of the Series B round included additional funding from founding investors, IP Group, Inc. and Penn Medicine, and new investor 4BIO Capital.